TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01833026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spirometry test
Description: For the initial visit for the intervention group, an initial demographics form and a health questionnaire will given to the subject to complete. To evaluate the breathing and quality of living, a spirometry test will be performed that will evaluate how well and how fast the subject can breath and blow out air.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spirometry test
Description: For the initial visit for the intervention group, an initial demographics form and a health questionnaire will given to the subject to complete. To evaluate the breathing and quality of living, a spirometry test will be performed that will evaluate how well and how fast the subject can breath and blow out air.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol
Description: The spirometry test will be performed with a breathing medication called Levalbuterol (Xopenex®). Levalbuterol is used in standard practice for COPD and is commonly used during spirometry.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levalbuterol
Description: The spirometry test will be performed with a breathing medication called Levalbuterol (Xopenex®). Levalbuterol is used in standard practice for COPD and is commonly used during spirometry.
Study: NCT02755662

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Retention Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Retention Device
Study: NCT04488601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Rapamycin in 2 different dosage forms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Rapamycin in 2 different dosage forms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT05480631

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autograft
Description: autologous bone placed in the defect and then be secured with mini-screws to fill the fracture defect gap

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autograft with addition of concenterated growth factor
Description: the bone particulate harvested from the donor site will then be mixed with concentrated growth factor to bridge the fracture defect.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: xenograft with concentrated growth factor
Description: xenogenic bovine bone particulate mixed with platelet-derived concentrated growth factor to be held in place of fracture defect site.
Study: NCT03801798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1102
Description: NAs antivirals+GC1102 180,000 IU
Study: NCT01299792

Intervention type: OTHER
Intervention: sonographic measurement of bladder wall thickness
Description: measurement of bladder wall thickness by ultrasound at different filling states of the bladder during urodynamic investigation
Study: NCT00751751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + hydrochlorothiazide, if necessary
Description: oral olmesartan medoxomil tablets taken once daily for 52 weeks + oral hydrochlorothiazide tablets, once daily, after 12 weeks if needed to control BP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan + hydrochlorothiazide, if necessary
Description: oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tablets, after 12 weeks, if needed to control BP.
Study: NCT03982628

Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal CT imaging
Description: Routine abdominal CT imaging
Study: NCT03801798

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GC1102 Placebo
Description: NAs antivirals+GC1102 Placebo
Study: NCT02021240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Study: NCT01563406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15 second scrub
Description: Scrub catheter hubs for 15 seconds before every access.
Study: NCT03411096

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quadratus lumborum block with normal saline
Description: After general anesthesia, an anesthesiologist will perform an quadratus lumborum block with normal saline (20cc) under ultrasound guidance.
Study: NCT03680066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral food challenge to foods with traces
Description: Subjects will undergo an open food challenge to 3 processed foods labeled with may contain traces. The following foods (similar for all patients) will be given in one dose in the size of a regular serving:~* cookies, max 30 g;~* chocolate, max 30 g;~* breakfast cereals, max 50 g.~Each meal will be administered with a 1 hour observation period in between and at the end.
Study: NCT01563406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15 second scrub
Description: Scrub catheter hubs for 15 seconds before every access.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 second scrub
Description: Scrub catheter hubs for 15 seconds before every access.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 second scrub
Description: Scrub catheter hubs for 15 seconds before every access.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.15% chlorhexidine/70% isopropyl alcohol
Description: 3.15% chlorhexidine gluconate in 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters during half of the study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.15% chlorhexidine/70% isopropyl alcohol
Description: 3.15% chlorhexidine gluconate in 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters during half of the study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol
Description: 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters for the other half of the study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol
Description: 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters for the other half of the study period.
Study: NCT03476928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2mg, once daily, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2mg, once daily, oral
Study: NCT03592589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal canula
Description: high flow nasal canula to obtain a positive expiratory pressure
Study: NCT02325128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep-enhancement of extinction memory
Description: Recent reports show that sleep promotes memory consolidation. The investigators' preliminary findings suggest sleep may enhance the therapeutic extinction memories acquired during exposure therapy. For sleep-enhancement of extinction memory, the current intervention uses post-exposure naps as a means to provide sleep in close temporal proximity to the encoding of memory for the extinction social exposure fears in individuals with severe social anxiety symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep-enhancement of extinction memory
Description: Recent reports show that sleep promotes memory consolidation. The investigators' preliminary findings suggest sleep may enhance the therapeutic extinction memories acquired during exposure therapy. For sleep-enhancement of extinction memory, the current intervention uses post-exposure naps as a means to provide sleep in close temporal proximity to the encoding of memory for the extinction social exposure fears in individuals with severe social anxiety symptoms.
Study: NCT01885104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol (PEG 3350)
Description: Oral 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl laxative tablets (rescue medication)
Description: 5.0 mg tablets, 1 to 3 tablets in a single daily dose, to be provided for use as rescue medication if participant has not had bowel movement for 72 hours after start of treatment.
Study: NCT04380766

Intervention type: PROCEDURE
Intervention: Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer
Description: Comparison between the pre-COVID and COVID groups of general, clinical, endoscopic and surgical outcomes

Intervention type: PROCEDURE
Intervention: Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer
Description: Comparison between the pre-COVID and COVID groups of general, clinical, endoscopic and surgical outcomes
Study: NCT03670693

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle strength and fatigue assessment
Description: Measurement of maximum voluntary isometric contraction of the quadricep muscle on a cybex isokinetic dynomometer. This will be followed by a fatigue assessment where the torque decrement over 20 isokinetic knee extensions at a fixed angular velocity will be quantified to assess muscle fatigue

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle strength and fatigue assessment
Description: Measurement of maximum voluntary isometric contraction of the quadricep muscle on a cybex isokinetic dynomometer. This will be followed by a fatigue assessment where the torque decrement over 20 isokinetic knee extensions at a fixed angular velocity will be quantified to assess muscle fatigue
Study: NCT01885104

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bisacodyl laxative tablets (rescue medication)
Description: 5.0 mg tablets, 1 to 3 tablets in a single daily dose, to be provided for use as rescue medication if participant has not had bowel movement for 72 hours after start of treatment.
Study: NCT00369928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-760564
Description: 100 mg BID, of oral PG-760564
Study: NCT03670693

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle strength and fatigue assessment
Description: Measurement of maximum voluntary isometric contraction of the quadricep muscle on a cybex isokinetic dynomometer. This will be followed by a fatigue assessment where the torque decrement over 20 isokinetic knee extensions at a fixed angular velocity will be quantified to assess muscle fatigue
Study: NCT04505319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEFINISSE CORE FILLER
Description: DEFINISSE CORE FILLER volume will be injected between 4.0 of 5.0 ml on the whole face (at the discretion of the treating physician to achieve an optimal aesthetic result).~A touch-up will be possible at the first follow-up visit (after one month) with a amount of product between 4.0 and 5.0 ml on the whole face
Study: NCT01903122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cevimeline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cevimeline
Study: NCT01720589

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melt (test oil)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn oil (control)
Study: NCT00075764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Given intramuscularly
Study: NCT02934841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sham
Study: NCT00842283

Intervention type: OTHER
Intervention: skin tissue sample
Description: skin tissue sample
Study: NCT00819000

Intervention type: DRUG
Intervention: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b
Description: MS therapies (listed above) used according to prescribers' instructions.
Study: NCT04607174

Intervention type: OTHER
Group type: OTHER
Intervention: Pathologic group
Description: Voluntary Activation level will be determined according to the interpolate twitch technique (ITT).~During isometric contractions (knee at 40° flexion), three electric shocks (doublets) will be delivered. The first shock will be delivered at rest before contraction. The second one will be delivered 3-4 s after the beginning of the effort. The third one will be delivered at rest 2-3 s after the contraction has ended. Two isometric contractions will be performed, with a 3-minute break.~Then, 3 consecutive continuous passive motion (CPM) extension-flexions of the knee joint (range 105-0°), and 3 isokinetic concentric contractions (ISOK) will be performed. During both CPM and ISOK an electric shock will be delivered during each repetition. The instant of stimulation will be determined in a way allowing the twitch moments to peak at exactly 40° of knee flexion during extension. The same procedure will be administered first to the affected limb, and then to the non-affected limb.
Study: NCT01482806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCBT+ISG/Collaborative Care
Description: Guided patient access to the Beating the Blues CCBT program plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants~These interventions will be delivered as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCBT/Collaborative Care
Description: Guided patient access to the Beating the Blues CCBT program.~This interventions will be provided as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference.
Study: NCT00588406

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ipratropium bromide
Description: 2.5 mg, one dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60mg PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: 60mg PO
Study: NCT03814369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmplifEYE
Description: AmplifEYE colonoscopy
Study: NCT00369928

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dose
Description: placebo, BID, oral for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-760564
Description: 25 mg BID, of oral PG-760564
Study: NCT04276831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscope McCoy
Description: Subjects who fulfill inclusion criteria will be intubated using laryngoscope McCoy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscope Macintosh
Description: Subjects who fulfill inclusion criteria will be intubated using laryngoscope Macintosh
Study: NCT02971072

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subacromial injection
Description: A subacromial injection consisting up 6 cc 0.5% Marcaine with Epinephrine and 1 cc DepoMedrol will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: A standardized six-week exercise protocol supervised by a physical therapist
Study: NCT01549028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile-based PR program.
Description: Patients will be trained and monitored by mobile-based pulmonary rehbailitation program. By mobile, patients could undergo exercise training at home and the information of training parameters will be send to investigator. Investigator could monitor these patients by mobile. Patients will return to visit physian and receive six-minutes walking test to measure outcomes 3 months and 1 year later after mobile-based pulmonary rehabilitation program.
Study: NCT04950933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huolingshengji Granules
Description: 1 bag of Huolingshengji Granules each time + 1 tablet of Riluzole tablet simulation agent each time, twice a day, orally;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole tablet
Description: Huolingshengji granules simulation agent 1 bag each time + Riluzole tablet 1 tablet each time, 2 times a day, orally.
Study: NCT01636453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent assisted coiling with the Liberty Stent
Description: Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
Study: NCT01680991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Multiple doses of obinutuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Multiple doses of obinutuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Multiple doses of obinutuzumab.
Study: NCT04227119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irrigated ablation catheter
Description: After completion of ablation, the ablation catheter will be serially positioned in the cardiac chambers (either the left or right side of the heart). The stop cock will be turned to the pressure transducer and waveforms will be stored corresponding to each chamber.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon tipped PA catheter
Description: After removal of the irrigated ablation catheter, a 5F balloon tipped PA catheter which will be positioned under fluoroscopic guidance in each previously evaluated chamber and the chambers will be measured again.
Study: NCT03677544

Intervention type: OTHER
Intervention: laparoscopic approach with an extended pelvic lymph
Description: Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation

Intervention type: OTHER
Intervention: laparoscopic approach with an extended pelvic lymph
Description: Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation
Study: NCT03353441

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Microencapsulated Sublingual Glycine (MSG)
Description: Glycine (MSG) tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose tablet manufactured to mimic Glycine (MSG) tablet
Study: NCT04602013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Body weight \<60kg: 3mg/kg IV Q3W; Body weight ≥60kg: 200mg IV Q3W. Every three weeks is a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy drugs include cisplatin and albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).~Dosing on the first day, one cycle every three weeks, a total of 2 cycles. Cisplatin (25mg/m2 IV D1-3 Q3W)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: The total dose is 60-66 Gy, divided into 30-33 times (2.0 Gy/f, 5 f per week).
Study: NCT03401216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNERGY 48 mm
Description: Material: Platinum-Chromium alloy. Stent strut thickness: 0.0029-0.0032 inches. Polymer carrier composed of PLGA (poly(DL-lactide-co-glycolide)). Drug product: Everolimus, 1µg per 1 mm2. Stent diameters available: 2.25; 2.50; 2.75; 3.00; 3.50; 4.00 mm. Stent length: 48 mm. Nominal balloon pressure: 11 atm. (1117 kPa). Manufacturing company: Boston Scientific Corporation (USA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNERGY 48 mm
Description: Material: Platinum-Chromium alloy. Stent strut thickness: 0.0029-0.0032 inches. Polymer carrier composed of PLGA (poly(DL-lactide-co-glycolide)). Drug product: Everolimus, 1µg per 1 mm2. Stent diameters available: 2.25; 2.50; 2.75; 3.00; 3.50; 4.00 mm. Stent length: 48 mm. Nominal balloon pressure: 11 atm. (1117 kPa). Manufacturing company: Boston Scientific Corporation (USA)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Standard PCI procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Standard PCI procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 month OCT follow-up
Description: Optical coherence tomography imaging of target vessel within 3 month after PCI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 6 month OCT follow-up
Description: Optical coherence tomography imaging of target vessel within 5 month after PCI
Study: NCT02177786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selonsertib
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selonsertib
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selonsertib
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match selonsertib
Description: Tablets administered orally once daily
Study: NCT01758172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Study: NCT03875872

Intervention type: DRUG
Intervention: Propofol
Description: Patients who had surgeries and were anaesthetized with propofol at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017

Intervention type: DRUG
Intervention: inhalation anaesthetics
Description: Patients who had surgeries and were anaesthetized via inhalation at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
Study: NCT02306941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Description: The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, adapted for adolescents with FAP/FD and their parents. Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
Study: NCT01402323

Intervention type: OTHER
Group type: OTHER
Intervention: time point of tooth extraction